Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Elivaldogene-tavalentivec (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions; Therapeutic Use
- 18 Sep 2019 According to a bluebird bio Media release, as of February 11, 2019, 47 patients who had undergone allo-HSCT were enrolled in this study.
- 18 Sep 2019 Results presented in a bluebird bio Media Release
- 18 Sep 2019 According to a bluebird bio Media release, data were presented at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece.